# Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial

> **NCT05596786** · PHASE3 · RECRUITING · sponsor: **University Hospital, Tours** · enrollment: 126 (estimated)

## Conditions studied

- Lung Diseases

## Interventions

- **DRUG:** Rituximab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05596786
- **Lead sponsor:** University Hospital, Tours
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-16
- **Primary completion:** 2026-07-16
- **Final completion:** 2026-07-16
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05596786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05596786, "Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05596786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*